EZH2 and graft versus host disease: This observation suggested that inhibition of EZH2 might be a reasonable approach to protect patients undergoing bone marrow transplantation from the development of GVHD without compromising the beneficial graft-versus-leukemia effect of allogeneic stem cell transplantation.